Balancing Safety, Cost, and Duration in Immunotherapy for NSCLC: Lauren Antrim, MD

Lauren Antrim, MD, emphasized the need to balance safety, efficacy, and financial considerations when managing immune checkpoint inhibitors in NSCLC, underscoring the importance of patient-centered discussions and ongoing trials to refine treatment duration strategies.